HIV Conferences: A Look Back at 2012

Six Promising HIV Drugs in the Pipeline

December 5, 2012

 < Prev  |  1  |  2  |  3 

New Fixed-Dose Combination and Antiretroviral Formulations

Gulick pointed out three one-pill, once-a-day formulations being developed:

  • GS-7340/FTC/elvitegravir/cobicistat.
  • GS-7340/FTC/darunavir/cobicistat.
  • Abacavir/lamivudine (3TC, Epivir)/dolutegravir.

In addition, three other in-development formulations that Gulick mentioned were:

  • Lopinavir/ritonavir/lamivudine.
  • Atazanavir (Reyataz)/cobicistat and darunavir/cobicistat (both in clinical trials).
  • Rilpivirine long-acting (RPV-LA).

Regarding the last drug in those lists, a small pilot study presented at CROI 2012 found that RPV-LA could potentially be given once a month in its long-acting nano-formation. It would likely need to be paired with other drugs, but research is ongoing for its use in treatment and prevention.

Warren Tong is the research editor for TheBody.com and TheBodyPRO.com.

Follow Warren on Twitter: @WarrenAtTheBody.

Copyright © 2012 Remedy Health Media, LLC. All rights reserved.
 < Prev  |  1  |  2  |  3 

This article was provided by TheBodyPRO.com. It is a part of the publication IDWeek 2012.

Reader Comments:

Comment by: Gary Whitmore (Ireland) Sun., Sep. 8, 2013 at 10:08 am UTC
Thanks to BIG PHARMA,Pfizer Glaxosmithkline(Viiv Healthcare} Gillead Science, Merck,JNJ ,etc,HIV is no longer a death sentence like it was in the 80s and early 90s,with the right Doctor and treatment you can now live a relatvily normal life and live in to your 70s,Thank you BIG PHARMA, and the Doctors who treat HIV+ patients.
Reply to this comment

Comment by: ranjan (India) Mon., May. 13, 2013 at 10:57 pm UTC
Could not have put it better. What I am hoping from so many breakthroughs of recent times is for atleast a treatment which can be say a shot once every 6 months with minimum side effects and targets only HIV and keeps it in control.This should keep even the drug companies happy
Reply to this comment

Comment by: Haziel (kgRioEutkRZeoRSBu) Thu., Jan. 10, 2013 at 6:50 am UTC
Theoretically all it takes is one virus getting into a cell. The virus is not very resintast to external elements, nor the body's natural defenses, so it is unlikely that you get infected by contact with only one virus, but it is possible. The comment about health-care workers and needle-stick injuries is a valid one. Depending on the level of infection even one ml of blood can hold tens of thousands of viruses
Reply to this comment

Comment by: Anthony (IkJJLTWJm) Wed., Jan. 9, 2013 at 8:48 am UTC
An interesting ascpet here is that "Gilead" has preferred an appeal from the order of the Controller under Section 25(1). Has the IPAB admitted the appeal; set a date for a hearing etc?While, it has been argued that decisons in pre-grant oppositions ought to be appealable before the IPAB(when read together with Section 15), there has been no clear Court direction so far.It would be helpful, if we know if the IPAB has entertained the appeal and if so, if it has given any reasons for doing so...
Reply to this comment

Comment by: maeza (sa ) Fri., Dec. 21, 2012 at 5:18 am UTC
Isit true that the is a Drug that defeats 80% of the virus in an infected person with HIV/AIDS??
Reply to this comment

Comment by: kisendi k (Tanzania) Fri., Dec. 21, 2012 at 3:47 am UTC
Thanks for the updates.
Reply to this comment

Comment by: Christopher B (Cambridge, MA) Thu., Dec. 20, 2012 at 1:17 pm UTC
As a note for Entry Inhibitors in development, we noticed that you included Ibalizumab, but you overlooked mention of PRO140, a monoclonal antibody to CCR5 that has just received a $10 Million NIH grant through a lab at Drexel University owned by CytoDyn Inc. and entering a new PhaseIIb trial starting early 2012
Reply to this comment

Comment by: AMROSE INNOCENT (KENYA) Mon., Dec. 17, 2012 at 3:30 am UTC
When will the new ARVs start circulating in the market?
Reply to this comment

Comment by: Sean (Dublin, Ireland) Fri., Dec. 14, 2012 at 6:35 am UTC
Thanks for this summary. It's good news to know that more and more drug options will be available when resistance sets in.

But the best news of all would be to hear of a new drug that will remove HIV from the body, entirely. This is where I want the work to be. I, and many others, need that drug SOON.
Reply to this comment

Comment by: michael (los angeles) Thu., Dec. 6, 2012 at 5:16 am UTC
interesting. a couple of these can actually be used as a basis for prep and help control the spread of the virus. ccr5 antagonists and integrase inhibotors that require only to be taken every few months can be game changers in terms of preventing the spread of the virus among sexually active groups....assuming of course it is affordable.
Reply to this comment
Replies to this comment:
Comment by: Shane (London, UK) Thu., Jan. 17, 2013 at 2:15 pm UTC
I am still waiting for CXCR4 inhibitors to surface since this is the type of receptor my HIV uses..I am thinking possibly that the CCR5 receptor viruses must be the majority that's why this class of drug is getting the priority?
..or basically CXCR4 HIV is the one more prevalent in non-western countries (although I am UK born & was infected in the UK from a UK born person), thus I notice from the past that this section of the HIV community always comes last since poor people/nations are not going to make the drug companies money!

I believe a CCR5 antagonist is not really a sure fire prophylaxis if taken on its own since a CXCR4 virus would completely ignore it? Besides, from reading a report yesterday about the Hep C/Meth/Mental Health crisis in London (which I already was well aware about) saying 60% of people getting Hep C solely through sex and not even injecting drugs..HIV should be the least of peoples worries..

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.